Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1181333 | 0.92 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2AGLALMNA | |
| SCHEMBL3302462 | 0.86 | LMNA (0.70) | ALDH1A1MEN1KMT2AGLALMNA | |
| SCHEMBL1182072 | 0.84 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2AGLALMNA | |
| SCHEMBL1182046 | 0.83 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2AGLALMNA | |
| SCHEMBL1182217 | 0.83 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2AGLALMNA | |
| SCHEMBL1182373 | 0.82 | ALDH1A1 (0.55) | ALDH1A1MEN1KMT2AGLALMNA | |
| SCHEMBL5314942 | 0.82 | LTA4H (0.73) | ALDH1A1MEN1KMT2AGLALMNA | |
| SCHEMBL3301180 | 0.82 | LMNA (0.68) | ALDH1A1MEN1KMT2AGLALMNA | |
| SCHEMBL5659325 | 0.82 | LMNA (0.70) | ALDH1A1MEN1KMT2AGLALMNA | |
| SCHEMBL1181541 | 0.82 | SMN1; SMN2 (0.56) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099703-A1 | PHENYLAMINO-SUBSTITUTED PIPERIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099703-A1 | PHENYLAMINO-SUBSTITUTED PIPERIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | PIGO, PNMT, CAT | ALDH1A1 170/4885MEN1 1483/4885KMT2A 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.